Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate changes in body composition and cardiometabolic risk factors in patients with mild autonomous cortisol secretion (MACS) who are treated with osilodrostat (Isturisa). Participants with MACS will undergo baseline and follow-up assessments, including DEXA scans, laboratory tests, blood pressure measurements, and clinical evaluations. The goal of this study is to determine whether blocking excess cortisol production improves metabolic outcomes, body fat distribution, and overall health in this patient population